Ichor CEO Delivered Lysoclear Update and Held Workshop at Annual LEAF Conference

Posted Posted in Icaria Life Sciences, Ichor, Lysoclear

12 July 2019  NEW YORK, NY: The second annual Life Extension Advocacy Foundation (LEAF) Ending Age Related Diseases Conference was held in New York City July 11-12th. This conference brought together many of the top minds in the biotechnology rejuvenation field, including Dr. Kelsey Moody, CEO at Ichor Therapeutics, Inc. Dr. Moody also held a workshop prior to the conference, on July 10th.   The workshop was held in the Cooper Union […]

Industry Leader Joins Ichor Therapeutics as Chief Medical Officer

Posted Posted in Antoxerene, Ichor, Lysoclear

Ichor Therapeutics, a pre-clinical contract research organization, recently announced the appointment of Cornelis (Cees) Hendrik Wortel MD, PhD to the position of Chief Medical Officer (CMO). Dr. Wortel brings over 25 years of experience to Ichor, having worked as a senior (bio) pharmaceutical executive for early stage and established companies, both nationally and internationally. Most notably, he has been involved in the development of Remicade® (the first anti-TNF biological drug) and in a very large number of clinical trials, Phase I to IV, bringing innovative first-in-class drugs to market.

Ichor to Present Double Feature at Undoing Aging Conference in Berlin

Posted Posted in Antoxerene, Ichor, Lysoclear

The 2018 Undoing Aging Conference, co-hosted by SENS Research Foundation and Michael Greve’s Forever Healthy Foundation, is a scientific forum focused on the cellular and molecular repair of age-related damage. It provides a platform for leading researchers from around the world to share their work in stem cells, senescent cells, immunotherapies, biomarkers, and drug discovery.

Ichor Nabs $600,000 Program Investment and New Partnerships in Wake of Company Expansion and Promising Early Results

Posted Posted in Ichor, Lysoclear

Age-related Macular Degeneration (AMD) is a presently incurable eye condition leading to partial loss of vision and affects as many as 15 million Americans and millions more globally. AMD has a significant impact on an individual’s quality of life through decreased independence and increased fall risk as well as the psychological and financial burden that vision loss can cause.